24 citations
,
September 2005 in “Journal of Cellular Biochemistry”
Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.